You are here: Industry Insights > Alzheimer

News List

FDA Grants Accelerated Approval for Alzheimer’s Drug fda.gov
June 09, 2021
Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.
Biogen applies for approval of Alzheimer’s drug, aducanumab in Japan expresspharma
December 11, 2020
Biogen said it has filed for regulatory approval in Japan for an Alzheimer’s disease drug it developed with local partner Eisai.
Happiness Biotech Starts Offering Kingdomway Coenzyme Q10 in Its Experience Stores prnasia
November 17, 2020
Happiness Biotech Group Limited announced that the Company's experience stores started offering Coenzyme Q10 - a best-selling product from Xiamen Kingdomway Group Company.
Positive Phase II results for CNS drug neflamapimod europeanpharmaceuticalreview
October 10, 2020
Neflamapimod taken three times a day significantly improved cognition in trial participants with mild-to-moderate dementia with Lewy bodies (DLB).
FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients americanpharmaceuticalreview
August 19, 2020
The U.S. Food and Drug Administration (FDA) notified India Globalization Capital (IGC) it has authorized the initiation Phase 1 human trial study for the Company’s investigational cannabinoid formulation for the treatment of patients suffering from ...
UCB Announces Alzheimer's Disease Treatment Coloration with Roche americanpharmaceuticalreview
August 05, 2020
UCB announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer's Disease (AD).
Roche and UCB partner to develop antibody therapy for Alzheimer’s pharmaceutical-technology
July 31, 2020
Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and commercialise an antibody treatment, UCB0107, for Alzheimer’s disease.
Novel anti-amyloid drug BAN2401 enters Phase III trial in Alzheimer’s patients europeanpharmaceuticalreview
July 23, 2020
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
Rotigotine improves cognitive function in Alzheimer’s patients europeanpharmaceuticalreview
July 17, 2020
In a study of 94 patients with mild-to-moderate Alzheimer’s disease, rotigotine improved frontal lobe executive function and enabled patients to independently perform daily activities.
Nanohybrid drug delivery vehicle could help treat Alzheimer’s europeanpharmaceuticalreview
April 29, 2020
The chitosan drug delivery vehicle could be used for administering polyphenol ellagic acid (EA), a potential antioxidant treatment for Alzheimer’s and Parkinson’s.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page